Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma. Issue 12 (22nd October 2019)

• Record Type: Journal Article
• Authors: Kimura, Kenji; Tanaka, Yugo; Tauchi, Shunsuke; Kitamura, Yoshitaka; Nishio, Wataru; Sakai, Yasuhiro; Hayashi, Yoshitake; Yoshimura, Masahiro; Maniwa, Yoshimasa
• Is Part Of: Thoracic cancer. Volume 10:Issue 12(2019)
• Page Start: 2300
• Page End: 2307
• Publication Date: 2019-10-22
• Subjects: Adjuvant chemotherapy -- biomarker -- lung cancer; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.13230
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract : Background: Partner of Sld five 3 (Psf3) is a member of the heterotetrameric complex that consists of SLD5, Psf1, Psf2, and Psf3. We have shown in previous studies that high Psf3 expression was a poor prognostic marker for pulmonary adenocarcinoma. Here, we statistically evaluated the relationship between clinicopathologic factors and Psf3 expression in stage I pulmonary adenocarcinoma. Methods: A total of 583 patients who had undergone complete resection of stage I pulmonary adenocarcinoma from January 2002 to December 2009 were included in the study. Tissue microarrays were performed, and the resected tumors were divided into groups according to Psf3 expression. Results: Of 583 patients, high expression of Psf3 was observed in 211 (36.2%) and low expression of Psf3 observed in 372 (63.8%) patients. Among stage I patients, the five‐year survival rate was 76.7% in the Psf3 high expression group and 90.9% in the Psf3 low expression group ( P < 0.0001). On multivariate analysis, Psf3 was found to be the independent prognostic factor. Among stage I patients in the Psf3 high expression group, a significantly greater five‐year survival rate was observed in patients who received postoperative chemotherapy with tegafur‐uracil than in those who underwent surgery alone ( P < 0.0001). In contrast, among stage I patients in the Psf3 low expression group, no difference was found in the five‐year survival, regardless of the presence or absence of tegafur‐uracil ( P = 0.873). Conclusion: The Psf3 expression was an independent prognostic factor and could be a biomarker of adjuvant tegafur‐uracil for stage I pulmonary adenocarcinoma. Key points: Significant findings of the study: The Psf3 expression could be a biomarker of adjuvant tegafur‐uracil administration for stage I pulmonary adenocarcinoma. What this study adds: Appropriate patients of adjuvant chemotherapy for stage I pulmonary adenocarcinoma using Psf3 expression could be selected.